Generic name: meningococcal (groups a, c, w-135 and y) crm197 oligosaccharide conjugate vaccine
Dosage form: injection
This dosage information does not include all the information needed to use Menveo safely and effectively. See full prescribing information for Menveo.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
MENVEO is supplied in two vials that must be combined prior to administration. MENVEO must be prepared for administration by reconstituting the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component. Using a graduated syringe, withdraw the entire contents of the vial of MenCYW-135 liquid conjugate component and inject into the MenA lyophilized conjugate component vial. Invert the vial and shake well until the vaccine is dissolved and then withdraw 0.5 mL of reconstituted product.
Please note that it is normal for a small amount of liquid to remain in the vial following withdrawal of the dose.
Following reconstitution, the vaccine is a clear, colorless solution, free from visible foreign particles. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If any of these conditions exist, MENVEO should not be administered.
The reconstituted vaccine should be used immediately, but may be held at or below 77°F (25°C) for up to 8 hours.
For intramuscular injection only. Do not administer MENVEO intravenously, subcutaneously or intradermally.
Dose and Schedule
MENVEO should be administered as a single 0.5mL intramuscular injection, preferably into the deltoid muscle (upper arm). For children 2 through 5 years of age at continued high risk of meningococcal disease a second dose may be administered 2 months after the first dose (sections 6.1, 14, 14.1). The duration of protection following immunization is not known.